在多发性硬化症中从抗CD20降级到克拉迪宾片:一项试点研究
Rosaria Sacco1, Giulio Disanto1, Emanuele Pravatà2
1Multiple Sclerosis Center (MSC), Department of Neurology, Neurocenter of Southern Switzerland, Lugano 6900, Switzerland.
Multiple sclerosis and related disorders
|November 7, 2024
概括
将多发性硬化症患者从抗CD20疗法转换为克拉迪布林维持了疗效,并防止了免疫球蛋白的减少. 这一策略对治疗多发性硬化有前途,同时减轻与长期B细胞枯竭相关的感染风险.
科学领域:
- 免疫学 免疫学 免疫学
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 对多发性硬化症 (MS) 进行长期的抗CD20抗体治疗与低血糖球蛋白血症和感染风险增加有关.
- 免疫球蛋白水平的不足,即高甘球蛋白血,会损害免疫系统对抗感染的能力.
研究的目的:
- 调查从抗CD20疗法转换为克拉迪宾作为一种预防多发性硬化症患者免疫球蛋白减少的策略.
- 评估克拉迪宾在多发性硬化症的抗CD20治疗后作为降级剂的疗效和安全性.
主要方法:
- 对血清免疫球蛋白G (IgG),免疫球蛋白M (IgM),神经丝光 (NfL) 和状纤维酸蛋白 (GFAP) 水平的前性分析.
- 该研究包括44名患者:14人从抗CD20药物转换为克拉迪宾,30人继续抗CD20治疗.
- 生物标志物水平在一年的时间内进行了监测.
主要成果:
- 血清IgG,IgM,NfL和GFAP水平在1年内转换为克拉迪宾的患者中保持稳定.
- 切换组中的生物标志物水平与继续抗CD20治疗的患者相似.
- 超过90%的患者仍然没有疾病活动,这表明治疗的持续有效性.
结论:
- 从抗CD20抗体转换为克拉迪宾是一种可行的策略,可以保持有效性,同时预防MS中的低二球蛋白血症.
- 克拉德里宾显示出作为降级剂的潜力,为减轻与MS中长期B细胞枯竭治疗相关的风险提供了一种方法.
- 进一步研究cladribine作为降级策略是多发性硬化症管理的必要条件.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
142
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
142
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
96
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
96